Objective: Non-coding RNAs are the RNAs with no protein coding function, long non-coding RNAs (LncRNAs) are the non-coding RNAs with more than 200 nucleotides. During the journey of discovering novel biomarkers for diagnosis of myocardial infarction (MI), the principle of studying the LncRNA as a potential would be always attractive, as it needs easy sample collection, has high detection sensitivity and high myocardial tissue specificity. Our main objective was to investigate the potential of LINC01538 as a novel diagnostic biomarker for MI. Material and Methods: Quantitative real-time polymerase chain reaction (RT-qPCR) was used to assess the expression of the serum LINC01538 in 50 ST Elevation MI (STEMI) patients and 48 controls. Results: The study showed a significant increase in serum level expression of LINC01538 in MI patients compared to controls [12 (6.6- 21.8) vs. 0.07 (0.01-0.2), p<0.001]. LINC01538 expression level in MI group was positively correlated with creatine kinase MB and high sensitive cardiac troponin I (hs-cTnI) (r=0.39, p=0.006 and r=0.22, p=0.007, respectively). Hs-cTnI found to have diagnostic value for MI with an area under curve (AUC) 0.917 [95% confidence interval (CI): 0.855- 0.979, p<0.001] at an optimal cutoff point of 1.45 ng/L, 90% sensitivity and 91% specificity. However, LINC01538 showed the highest diagnostic value with an AUC 0.980 (95% CI: 0.942- 1, p<0.001) at an optimal cut-off point of 1.76, 100% sensitivity and 98% specificity. Conclusion: Our findings have, for the first time, demonstrated that circulating LINC01538 are highly expressed in patients with MI, functioning as potential novel biomarker for diagnosis.
Keywords: LncRNA; LINC01538; novel biomarker; myocardial infarction
Amaç: Kodlamayan RNA'lar protein kodlama işlevi olmayan RNA'lardır, uzun kodlamayan RNA'lar (LncRNA'lar), 200'den fazla nükleotid içeren kodlamayan RNA'lardır. Miyokard enfarktüsünün (MI) tanısı için yeni biyobelirteçleri keşfetme yolculuğu sırasında, LncRNA'yı bir potansiyel olarak inceleme ilkesi, kolay örnek toplamaya ihtiyaç duyduğundan, yüksek algılama duyarlılığına ve yüksek miyokardiyal dolarak LINC01538'in potansiyelini araştırmaktır. Gereç ve Yöntemler: Elli ST yükselmeli MI (STEMI) hoku özgüllüğüne sahip olduğundan her zaman çekici olacaktır. Asıl amacımız MI için yeni bir biyobelirteç astası ve 48 kontrolde serum LINC01538 ekspresyonunu değerlendirmek için kantitatif gerçek zamanlı polimeraz zincir reaksiyonu (RT-qPCR) kullanıldı. Bulgular: MI hastalarında kontrollere kıyasla serum LINC01538 düzeylerinde anlamlı artış olduğu görüldü [12 (6.6-21.8) vs. 0.07 (0.01-0.2), p<0.001]. MI grubunda LINC01538 ekspresyon düzeyi kreatin kinaz MB ve yüksek sensitif kardiyak troponin I (hs-cTnI) ile pozitif olarak körele idi [sırasıyla, 12 (6.6-21.8) vs. 0.07 (0.01-0.2), p<0.001]. Hs-cTnI, eğri altında kalan alan (AUC) 0,917 [%95 güven aralığı (GA): 0,855-0,979, p<0,001] ile 1,45 ng/L optimal kesme noktasında, %90 duyarlılık ve %91 özgüllük ile MI için tanısal değere sahip bulundu. Bununla birlikte, LINC01538, 1,76 optimal kesme noktasında, %100 duyarlılık ve %98 özgüllükte AUC 0.980 (%95 CI: 0.942-1, p<0.001) ile en yüksek tanı değerini göstermiştir. Sonuç: Bulgularımız, ilk kez, dolaşımdaki LINC01538'in MI hastalarında yüksek oranda eksprese edildiğini ve tanı için potansiyel yeni bir biyobelirteç olarak işlev gördüğünü göstermiştir. Bununla birlikte, potansiyel uygulamayı doğrulamak ve tutarlılığı belirlemek için ST elevasyonsuz akut koroner sendromda test edilmesi gerekir.
Anahtar Kelimeler: LncRNA; LINC01538; yeni biyobelirteç; myokard enfarktüsü
- Del Re DP, Amgalan D, Linkermann A, Liu Q, Kitsis RN. Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99(4):1765-817. [Crossref] [PubMed] [PMC]
- Xie L, Zhang Q, Mao J, Zhang J, Li L. The Roles of lncRNA in Myocardial Infarction: Molecular Mechanisms, Diagnosis Biomarkers, and Therapeutic Perspectives. Front Cell Dev Biol. 2021;9:680713. [Crossref] [PubMed] [PMC]
- Wang XM, Li XM, Song N, Zhai H, Gao XM, Yang YN. Long non-coding RNAs H19, MALAT1 and MIAT as potential novel biomarkers for diagnosis of acute myocardial infarction. Biomed Pharmacother. 2019;118:109208. [Crossref] [PubMed]
- Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, et al. Reducing the global burden of cardiovascular disease, part 2: prevention and treatment of cardiovascular disease. Circ Res. 2017;121(6):695-710. [Crossref] [PubMed]
- Puthanveetil P, Chen S, Feng B, Gautam A, Chakrabarti S. Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med. 2015;19(6):1418-25. [Crossref] [PubMed] [PMC]
- Park KC, Gaze DC, Collinson PO, Marber MS. Cardiac troponins: from myocardial infarction to chronic disease. Cardiovasc Res. 2017;113(14):1708-18. [Crossref] [PubMed] [PMC]
- Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting CC, Alexanian M, et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med. 2017;9(395):eaai9118. [Crossref] [PubMed] [PMC]
- Yeh CF, Chang YE, Lu CY, Hsuan CF, Chang WT, Yang KC. Expedition to the missing link: Long noncoding RNAs in cardiovascular diseases. J Biomed Sci. 2020;27(1):48. [Crossref] [PubMed] [PMC]
- Delás MJ, Hannon GJ. lncRNAs in development and disease: from functions to mechanisms. Open Biol. 2017;7(7):170121. [Crossref] [PubMed] [PMC]
- Koch L. Functional genomics: Screening for lncRNA function. Nat Rev Genet. 2017;18(2):70. [Crossref] [PubMed]
- Panzeri I, Rossetti G, Abrignani S, Pagani M. Long intergenic non-coding RNAs: novel drivers of human lymphocyte differentiation. Front Immunol. 2015;6:175. [Crossref] [PubMed] [PMC]
- Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014;115(7):668-77. [Crossref] [PubMed]
- Li M, Wang YF, Yang XC, Xu L, Li WM, Xia K, et al. Circulating long noncoding RNA LIPCAR acts as a novel biomarker in patients with ST-segment elevation myocardial infarction. Med Sci Monit. 2018;24:5064-70. [Crossref] [PubMed] [PMC]
- Schulte C, Barwari T, Joshi A, Zeller T, Mayr M. Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. Trends Mol Med. 2020;26(6):583-96. [Crossref] [PubMed]
- Li L, Wang L, Li H, Han X, Chen S, Yang B, et al. Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease. Atherosclerosis. 2018;275:359-67. [Crossref] [PubMed]
- Su Y, Li L, Zhao S, Yue Y, Yang S. The long noncoding RNA expression profiles of paroxysmal atrial fibrillation identified by microarray analysis. Gene. 2018;642:125-34. [Crossref] [PubMed]
- Xiao J, Shen B, Li J, Lv D, Zhao Y, Wang F, et al. Serum microRNA-499 and microRNA-208a as biomarkers of acute myocardial infarction. Int J Clin Exp Med. 2014;7(1):136-41. [PubMed] [PMC]
- Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31(6):659-66. [Crossref] [PubMed]
- Li X, Xiang DK, Shu YZ, Feng CH. Dysregulated pathways for off-pump coronary artery bypass grafting. Open Life Sciences. 2017;12(1):399-405. [Crossref]
- Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. [PubMed]
- Viereck J, Thum T. Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury. Circ Res. 2017;120(2):381-99. [Crossref] [PubMed]
- Correia CCM, Rodrigues LF, de Avila Pelozin BR, Oliveira EM, Fernandes T. Long non-coding RNAs in cardiovascular diseases: potential function as biomarkers and therapeutic targets of exercise training. noncoding RNA. 2021;7(4):65. [Crossref] [PubMed] [PMC]
- Chen G, Wang Z, Wang D, Qiu C, Liu M, Chen X, et al. LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res. 2013;41(Database issue):D983-6. [Crossref] [PubMed] [PMC]
- Yan Y, Zhang B, Liu N, Qi C, Xiao Y, Tian X, et al. Circulating long noncoding RNA UCA1 as a novel biomarker of acute myocardial infarction. Biomed Res Int. 2016;2016:8079372. [Crossref] [PubMed] [PMC]
- Gao L, Liu Y, Guo S, Yao R, Wu L, Xiao L, et al. Circulating long noncoding RNA HOTAIR is an essential mediator of acute myocardial infarction. Cell Physiol Biochem. 2017;44(4):1497-508. [Crossref] [PubMed]
- Liu K, Zhao D, Wang D. LINC00528 regulates myocardial infarction by targeting the miR-143-3p/COX-2 axis. Bioengineered. 2020;11(1):11-8. [Crossref] [PubMed] [PMC]
- Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014;114(10):1569-75. [Crossref] [PubMed]
.: Process List